Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » Research » 4th World Theranostics Congress Wrap Up

4th World Theranostics Congress Wrap Up

  • December 21, 2016
Thanks to an internationally commended Scientific Program facilitated by Prof Michael Hofman (Peter Mac), Prof Rod Hicks (Peter Mac) and Prof Richard Baum (Germany), the conference welcomed close to 400 delegates from 35 countries.

With a focus on advancements in treatment of Neuroendocrine (NET) cancer on day one and Prostate cancer on day two, the speaker presentations included:

Refining and Defining NET Targets
Chairs: Prof Frank Roesch, Prof Irina Velikyan

– Integrating cancer genomics with imaging
Dr Ben Lawrence, Auckland City Hospital
– Production of Ga-68 radiotracers under GMP and regulatory aspects – A German perspective
Dr Oliver Neels, German Cancer Research Centre (DKFZ) Heidelberg
– Optimised production of 64Cu-SARTATE for a phase 1 clinical trial
Charmaine Jeffery, Clarity Pharmaceuticals
– Influence of the radiopharmaceutical affinity and peptide content on the pharmacokinetics: (68Ga)Ga-DOTATOC and (68Ga)Ga-DOTATATE
Irina Velikyan, Uppsala University Hospital

Optimising Peptide Receptor Radionuclide Therapy (PRRT)
Chairs: Prof Harvey Turner, Dr Grace Kong

-Two Decades of THERANOSTICS in Neuroendocrine Tumors – Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT)
Dr Harshad R Kulkarni on behalf of Prof Richard Baum, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka
– NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis
Prof Jonathan Strosberg, Moffitt Cancer Center
-Clinical Perspective: The “difficult development situation”: how to approach and overcome challenges from a regulatory perspective
Hans-Georg Eichler, European Medicines Agency 
-The Cruel Wait for PRRT
Paul Stephenson, The Unicorn Foundation

For the full program please click here

To watch all the presentations from day 1 – Focus on Neuroendocrine Tumors please click here

The feedback from the attendees was incredibly positive and special thanks to Charlotte Rhiane for her incredible performance at the Conference dinner. Charlotte is a friend of the Unicorn Foundation and her personal touch telling her story about her dad and his battle with NET Cancer was so appreciated by everyone present.

Thanks to the organising committee for their hard work and ASN Events for their professionalism in bringing the conference together.

If you missed a speaker or would like to watch the presentation again we will have all the videos available on our You Tube channel soon. Will send out a notification when available.  The 5th World Theranostics Congress will be held in South Korea in early 2018 and we wish the hosts a successful meeting.

Lastly thank you also to the major sponsors for their support:

Platinum Sponsor

Gold Sponsor

 

 Silver Sponsors

       

 Bronze Sponsor

 

 Speaker Sponsors

             

 

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousCommNETS Update from our NET Nurse Kate Wakelin
NextUF $1 million dollar research fundNext

Related Posts

NECA at ENETS 2025: Advancing NET Care on the Global Stage

NeuroEndocrine Cancer Australia at ENETS 2025: Advancing NET Care on the Global Stage NeuroEndocrine Cancer Australia (NECA) proudly represented Australia at the 22nd Annual European

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin